Source: Cystic Fibrosis Foundation
An expanded access program for a potential new CF drug, Kalydeco™ (VX-770), is now available at participating clinical sites throughout the country for people with the G551D mutation who have highly limited lung function and may benefit from treatment.
Vertex Pharmaceuticals, Inc., the maker of Kalydeco (kuh-LYE-deh-koh), created this program for patients while awaiting review of the drug by the U.S. Food and Drug Administration (FDA).
The company is seeking FDA approval for Kalydeco in people ages 6 and older with at least one copy of the G551D mutation.
People with CF who may be eligible for this program and want more information should talk to their CF doctor or call the Vertex Expanded Access Call Center at 1-800-745-4484.
Kalydeco is an oral drug in development that targets the underlying cause of cystic fibrosis. Kalydeco was developed by Vertex with CF Foundation support and research input.